Phaseline

Targets › BMP7

BMP7 (Bone morphogenetic protein 7): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Other; next expected readout Jan 2028.

Growth factor of the TGF-beta superfamily that plays important role in various biological processes, including embryogenesis, hematopoiesis, neurogenesis and skeletal morphogenesis. Initiates the canonical BMP signaling cascade by associating with type I receptor ACVR1 and type II receptor ACVR2A. Once all three components are bound together in a complex at the cell surface, ACVR2A phosphorylates and activates ACVR1. (UniProt, P18075)

Open in Phaseline: the race on BMP7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The University of Texas Health Science Center, HoustonDemineralized Bone Matrix/Bone Morphogenic Protein (DBM/BMP)
Bone morphogenic protein with demineralized bone matrix to promote alveolar bone formation
BMP2, BMP7Phase 4Cleft Lip and PalateJan 2028

Conditions

Cleft Lip and Palate (1)

Modalities

small molecule (1)

Companies

The University of Texas Health Science Center, Houston (1)

Related targets

BMP2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.